RATIONALE: Hypertrophic cardiomyopathy occurs with a frequency of about 1 in 500 people. Approximately 30% of those affected carry mutations within the gene encoding cMyBP-C (cardiac myosin binding protein C). Cardiac stress, as well as cMyBP-C mutations, can trigger production of a 40kDa truncated fragment derived from the amino terminus of cMyBP-C (Mybpc340kDa). Expression of the 40kDa fragment in mouse cardiomyocytes leads to hypertrophy, fibrosis, and heart failure. Here we use genetic approaches to establish a causal role for excessive myofibroblast activation in a slow, progressive genetic cardiomyopathy-one that is driven by a cardiomyocyte-intrinsic genetic perturbation that models an important human disease. OBJECTIVE: TGFβ (transforming growth factor-β) signaling is implicated in a variety of fibrotic processes, and the goal of this study was to define the role of myofibroblast TGFβ signaling during chronic Mybpc340kDa expression. METHODS AND RESULTS: To specifically block TGFβ signaling only in the activated myofibroblasts in Mybpc340kDa transgenic mice and quadruple compound mutant mice were generated, in which the TGFβ receptor II (TβRII) alleles ( Tgfbr2) were ablated using the periostin ( Postn) allele, myofibroblast-specific, tamoxifen-inducible Cre ( Postnmcm) gene-targeted line. Tgfbr2 was ablated either early or late during pathological fibrosis. Early myofibroblast-specific Tgfbr2 ablation during the fibrotic response reduced cardiac fibrosis, alleviated cardiac hypertrophy, preserved cardiac function, and increased lifespan of the Mybpc340kDa transgenic mice. Tgfbr2 ablation late in the pathological process reduced cardiac fibrosis, preserved cardiac function, and prolonged Mybpc340kDa mouse survival but failed to reverse cardiac hypertrophy. CONCLUSIONS: Fibrosis and cardiac dysfunction induced by cardiomyocyte-specific expression of Mybpc340kDa were significantly decreased by Tgfbr2 ablation in the myofibroblast. Surprisingly, preexisting fibrosis was partially reversed if the gene was ablated subsequent to fibrotic deposition, suggesting that continued TGFβ signaling through the myofibroblasts was needed to maintain the heart fibrotic response to a chronic, disease-causing cardiomyocyte-only stimulus.
RATIONALE: Hypertrophic cardiomyopathy occurs with a frequency of about 1 in 500 people. Approximately 30% of those affected carry mutations within the gene encoding cMyBP-C (cardiac myosin binding protein C). Cardiac stress, as well as cMyBP-C mutations, can trigger production of a 40kDa truncated fragment derived from the amino terminus of cMyBP-C (Mybpc340kDa). Expression of the 40kDa fragment in mouse cardiomyocytes leads to hypertrophy, fibrosis, and heart failure. Here we use genetic approaches to establish a causal role for excessive myofibroblast activation in a slow, progressive genetic cardiomyopathy-one that is driven by a cardiomyocyte-intrinsic genetic perturbation that models an important human disease. OBJECTIVE: TGFβ (transforming growth factor-β) signaling is implicated in a variety of fibrotic processes, and the goal of this study was to define the role of myofibroblast TGFβ signaling during chronic Mybpc340kDa expression. METHODS AND RESULTS: To specifically block TGFβ signaling only in the activated myofibroblasts in Mybpc340kDa transgenic mice and quadruple compound mutant mice were generated, in which the TGFβ receptor II (TβRII) alleles ( Tgfbr2) were ablated using the periostin ( Postn) allele, myofibroblast-specific, tamoxifen-inducible Cre ( Postnmcm) gene-targeted line. Tgfbr2 was ablated either early or late during pathological fibrosis. Early myofibroblast-specific Tgfbr2 ablation during the fibrotic response reduced cardiac fibrosis, alleviated cardiac hypertrophy, preserved cardiac function, and increased lifespan of the Mybpc340kDa transgenic mice. Tgfbr2 ablation late in the pathological process reduced cardiac fibrosis, preserved cardiac function, and prolonged Mybpc340kDa mouse survival but failed to reverse cardiac hypertrophy. CONCLUSIONS:Fibrosis and cardiac dysfunction induced by cardiomyocyte-specific expression of Mybpc340kDa were significantly decreased by Tgfbr2 ablation in the myofibroblast. Surprisingly, preexisting fibrosis was partially reversed if the gene was ablated subsequent to fibrotic deposition, suggesting that continued TGFβ signaling through the myofibroblasts was needed to maintain the heart fibrotic response to a chronic, disease-causing cardiomyocyte-only stimulus.
Entities:
Keywords:
bone morphogenetic protein; fibrosis; myofibroblast; myosin; transforming growth factor
Authors: Federica Accornero; Jop H van Berlo; Robert N Correll; John W Elrod; Michelle A Sargent; Allen York; Joseph E Rabinowitz; Andrew Leask; Jeffery D Molkentin Journal: Mol Cell Biol Date: 2015-04-13 Impact factor: 4.272
Authors: L Carrier; G Bonne; E Bährend; B Yu; P Richard; F Niel; B Hainque; C Cruaud; F Gary; S Labeit; J B Bouhour; O Dubourg; M Desnos; A A Hagège; R J Trent; M Komajda; M Fiszman; K Schwartz Journal: Circ Res Date: 1997-03 Impact factor: 17.367
Authors: J Erdmann; S Daehmlow; S Wischke; M Senyuva; U Werner; J Raible; N Tanis; S Dyachenko; M Hummel; R Hetzer; V Regitz-Zagrosek Journal: Clin Genet Date: 2003-10 Impact factor: 4.438
Authors: Onur Kanisicak; Hadi Khalil; Malina J Ivey; Jason Karch; Bryan D Maliken; Robert N Correll; Matthew J Brody; Suh-Chin J Lin; Bruce J Aronow; Michelle D Tallquist; Jeffery D Molkentin Journal: Nat Commun Date: 2016-07-22 Impact factor: 14.919
Authors: Huan Liu; Shuya Zhang; Suowen Xu; Marina Koroleva; Eric M Small; Zheng Gen Jin Journal: Biochem Biophys Res Commun Date: 2019-05-10 Impact factor: 3.575
Authors: Athiththan Yogeswaran; Christian Troidl; James W McNamara; Jochen Wilhelm; Theresa Truschel; Laila Widmann; Muhammad Aslam; Christian W Hamm; Sakthivel Sadayappan; Christoph Lipps Journal: Cells Date: 2021-05-26 Impact factor: 6.600